Surgery: light – thermal – and electrical application – Light – thermal – and electrical application – Electrical therapeutic systems
Reexamination Certificate
2004-02-24
2009-06-23
Layno, Carl H (Department: 3766)
Surgery: light, thermal, and electrical application
Light, thermal, and electrical application
Electrical therapeutic systems
C607S002000, C607S058000
Reexamination Certificate
active
07551964
ABSTRACT:
A method for the treatment of obesity or other disorders by electrical activation or inhibition of the sympathetic nervous system is disclosed. This activation or inhibition can be accomplished by stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using an electrode. This nerve activation can result in reduced food intake and increased energy expenditure.
REFERENCES:
patent: 3911930 (1975-10-01), Hagfors et al.
patent: 4573481 (1986-03-01), Bullara
patent: 4595010 (1986-06-01), Radke
patent: 4827935 (1989-05-01), Geddes et al.
patent: 4867164 (1989-09-01), Zabara
patent: 5095905 (1992-03-01), Klepinski
patent: 5107833 (1992-04-01), Barsness
patent: 5154172 (1992-10-01), Terry, Jr. et al.
patent: 5179950 (1993-01-01), Stanislaw
patent: 5186170 (1993-02-01), Varrichio et al.
patent: 5188104 (1993-02-01), Wernicke et al.
patent: 5205285 (1993-04-01), Baker, Jr.
patent: 5215086 (1993-06-01), Terry, Jr. et al.
patent: 5215089 (1993-06-01), Baker, Jr.
patent: 5222494 (1993-06-01), Baker, Jr.
patent: 5231988 (1993-08-01), Wernicke et al.
patent: 5235980 (1993-08-01), Varrichio et al.
patent: 5237991 (1993-08-01), Baker, Jr. et al.
patent: 5251634 (1993-10-01), Weinberg
patent: 5263480 (1993-11-01), Wernicke et al.
patent: 5269303 (1993-12-01), Wernicke et al.
patent: 5299569 (1994-04-01), Wernicke et al.
patent: 5304206 (1994-04-01), Baker, Jr. et al.
patent: 5330515 (1994-07-01), Rutecki et al.
patent: 5335657 (1994-08-01), Terry, Jr. et al.
patent: 5351394 (1994-10-01), Weinberg
patent: 5423872 (1995-06-01), Cigaina
patent: 5454840 (1995-10-01), Krakovsky et al.
patent: 5458626 (1995-10-01), Krause
patent: 5531778 (1996-07-01), Maschino et al.
patent: 5540730 (1996-07-01), Terry, Jr. et al.
patent: 5540734 (1996-07-01), Zabara
patent: 5571150 (1996-11-01), Wernicke et al.
patent: 5690691 (1997-11-01), Chen et al.
patent: 5707400 (1998-01-01), Terry, Jr. et al.
patent: 5716392 (1998-02-01), Bourgeois et al.
patent: 5725563 (1998-03-01), Klotz
patent: 5755750 (1998-05-01), Petruska et al.
patent: 5782798 (1998-07-01), Rise
patent: 5836994 (1998-11-01), Bourgeois
patent: 5861014 (1999-01-01), Familoni
patent: 5919216 (1999-07-01), Houben et al.
patent: 5928272 (1999-07-01), Adkins et al.
patent: 5995872 (1999-11-01), Bourgeois
patent: 6041258 (2000-03-01), Cigaina
patent: 6068596 (2000-05-01), Weth et al.
patent: 6109269 (2000-08-01), Rise et al.
patent: 6129685 (2000-10-01), Howard, III
patent: 6146391 (2000-11-01), Cigaina
patent: 6165180 (2000-12-01), Cigaina
patent: 6169924 (2001-01-01), Meloy et al.
patent: 6308105 (2001-10-01), Duysens et al.
patent: 6321124 (2001-11-01), Cigaina
patent: 6350455 (2002-02-01), Donovan
patent: 6356786 (2002-03-01), Rezai et al.
patent: 6356787 (2002-03-01), Rezai et al.
patent: 6381495 (2002-04-01), Jenkins
patent: 6438423 (2002-08-01), Rezai et al.
patent: 6497718 (2002-12-01), Dewan
patent: 6558320 (2003-05-01), Causey et al.
patent: 6587719 (2003-07-01), Barrett et al.
patent: 6721603 (2004-04-01), Zabara et al.
patent: 6885888 (2005-04-01), Rezai
patent: 6912419 (2005-06-01), Hill et al.
patent: 7076292 (2006-07-01), Forsberg
patent: 7155278 (2006-12-01), King et al.
patent: 2001/0014815 (2001-08-01), Matsumura et al.
patent: 2002/0072780 (2002-06-01), Foley
patent: 2002/0077675 (2002-06-01), Greenstein
patent: 2002/0099419 (2002-07-01), Cohen et al.
patent: 2003/0018367 (2003-01-01), DiLorenzo
patent: 2003/0045909 (2003-03-01), Gross et al.
patent: 2003/0144708 (2003-07-01), Starkebaum
patent: 2003/0181958 (2003-09-01), Dobak, III
patent: 2004/0230255 (2004-11-01), Dobak, III
patent: 2005/0143788 (2005-06-01), Yun et al.
patent: 2005/0149146 (2005-07-01), Boveja et al.
patent: WO 98/57701 (1998-12-01), None
patent: WO 00/61223 (2000-10-01), None
patent: WO 01/52932 (2001-07-01), None
patent: WO 01/58520 (2001-08-01), None
patent: WO 01/83028 (2001-11-01), None
patent: WO 02/04068 (2002-01-01), None
patent: WO 02/26315 (2002-04-01), None
patent: WO 02/26317 (2002-04-01), None
patent: WO 02/34331 (2002-05-01), None
patent: WO 02/43467 (2002-06-01), None
patent: WO 02/062291 (2002-08-01), None
Kurose, T. et al.,Gulcagon, insulin and somatostatin secretion in response to sympathetic neuralactivation in streptozotocin-induced diabetic rats. A study with the isolatedperfused rat pancreas in vitro. Diabetologia Nov. 1992; 35(11): 1035-41.
Kaneto, A., et al.,Effect of splanchnic nerve stimulation on glucagons and insulin output in the dog, Endocrinolgy Jan. 1975; 96(1): 143-50.
Opsahl, Charles A.,Department of Psychology, Yale University, New Haven Connecticut 06520, Jul. 7, 1976, “Sympathetic nervous system involvement in the lateral hypothalamic lesion syndrome.”
Itina, L.V.,Sechenov Physiological Journal of the USSR, Institute of Physiology Acad. Sci.Belorus. SSR, Minsk, 1979, “Sympatho-activatory and sympatho-inhibitory afferent fibers of vagus and splanchnic nerves.” (Russian text with English abstract).
Itina, L.V., et al.,Sechnov Physiological Journal of the USSR, Institute of Physiology Acad. Sci.BSSR, Minsk, 1972, “Impulsation of the splanchnic and vagus nerves after introduction of fat into the lumen of the small intestine.” (Russian text with English abstract).
Shimazu, T.,Diabetologia, (1981) 20: 343-356, “Central Nervous System Regulation of Liver and Adipose Tissue Metabolism.”
Rozman, J., et al.,National Library of Medicine; Physiol Meas., Nov. 2002; 23(4):695-705, “Recording of ENGs from the nerves innervating the pancreas of a dog during the intravenous glucose tolerance test.”
Ahren, B.,Diabetologia, (2000) 43: 393-410, “Autonomic regulation of islet hormone secretion—Implications for health and disease.”
Bolte, E. et al., “Steroid Production from Plasma Cholesterol. II In Vivo Conversion of Plasma Cholesterol to Ovarian Progesterone and Adrenal C10 and C21 Steroids in Humans”, JCE&M, vol. 38, No. 3,(1974), pp. 394-400.
Chen, KE et al., “Induction of Leptin Resistance Through Direct Interaction of C-Reactive Protein with Leptin”, Nature Medicine, vol. 12, No. 4,(2006), pp. 425-432.
Clutter, William E., “Epinephrine Plasma Metabolic Clearance Rates and Physiologic Thresholds for Metabolic and Hemodynamic Actions in Man”, Journal of Clinic Investigations, vol. 66,(1980), pp. 94-101.
Mirkin, Bernard L., “Factors Influencing the Selective of Adrenal Medullary Hormones”, Journal Pharmacol. Exp. Ther., vol. 132,(1960), pp. 218-225.
Ravussin, Eric “Reduced Rate of Energy Expenditure as a Risk Factor for Body-Weight Gain”, New England Journal of Medicine, vol. 318,(1988), pp. 467-472.
Staten, M. A., “Physiological Increments in Epinephrine Stimulate Metabolic Rate in Humans”, Am. J. Physiol., vol. 253,(Nov. 1986), pp. 322-330.
Tataranni, P. “From Physiology to Neuroendocrinology: A Reappraisal of Risk Factors of Body Weight Gain in Humans”, Diabetes and Metabolism, vol. 24 No. 2,(1998), pp. 108-115.
Mokdad, A “The Continuing Epidemics of Obesity and Diabetes in the United States”, Journal of the American Medical Association, vol. 286, No. 10, (Sep. 2001), pp. 1195-1200.
Sjostrom, L “Epinephrine Sensitivity with respect to Metabolic Rate and Other Variables in Women”, American Journal of Physiology, vol. 245., (Sep. 1982), pp. E431-E442.
Katzeff, H “Metabolic Studies in Human Obesity during Overnutrition and Undernutrition: Thermogenic and Hormonal Responses to Norepinephrine, Metabolism”, vol. 35, No. 2., (Feb. 1986), pp. 166-175.
Leibel, R. “Changes in Energy Expenditure Resulting from Altered Body Weight”, The New England Journal of Medicine, vol. 332, No. 10., (Mar. 1995), pp. 621-628.
Matthews, D. “Effect of Epinephrine on Amino Acid and Energy Metabolism in Humans”, American Journal of Physiology, vol. 258., (Sep. 1989), pp. E948-E956.
Ratheiser, K. “Epinephrine Produces a Prolonged Elevation in Metabolic Rate in Humans”,
Hill James W.
Layno Carl H
Lee Yun Haeng
Leptos Biomedical, Inc.
Taylor Craig F.
LandOfFree
Splanchnic nerve stimulation for treatment of obesity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Splanchnic nerve stimulation for treatment of obesity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Splanchnic nerve stimulation for treatment of obesity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4147585